467 related articles for article (PubMed ID: 34364814)
1. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Moretto R; Rossini D; Capone I; Boccaccino A; Perrone F; Tamborini E; Masi G; Antoniotti C; Marmorino F; Conca V; Borelli B; Martignetti A; Pecora I; Simionato F; Cupini S; Ambrosini M; Manca P; Pietrantonio F; Falcone A; Cremolini C
Clin Colorectal Cancer; 2021 Dec; 20(4):314-317. PubMed ID: 34364814
[TBL] [Abstract][Full Text] [Related]
2. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
[TBL] [Abstract][Full Text] [Related]
3. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y
BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908
[TBL] [Abstract][Full Text] [Related]
4. Negative Hyperselection of Patients With
Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
[TBL] [Abstract][Full Text] [Related]
6. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
7. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
[TBL] [Abstract][Full Text] [Related]
10. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
11. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
Siu HWD; Tebbutt N; Chantrill L; Karapetis C; Steer C; Wilson K; Espinoza D; Bailey L; Yip S; Cuff J; Pavlakis N; Thavaneswaran S; Briscoe K; Srivastav R; Shannon J; Segelov E; Tie J; Caird S; Francesconi A; Price T; Wuttke M; Ladwa R; Sjoquist K; Burge M
BMC Cancer; 2021 Aug; 21(1):932. PubMed ID: 34407800
[TBL] [Abstract][Full Text] [Related]
12. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
Battaglin F; Schirripa M; Buggin F; Pietrantonio F; Morano F; Boscolo G; Tonini G; Lutrino ES; Lucchetti J; Salvatore L; Passardi A; Cremolini C; Arnoldi E; Scartozzi M; Pella N; Boni L; Bergamo F; Zagonel V; Loupakis F; Lonardi S
BMC Cancer; 2018 Jan; 18(1):98. PubMed ID: 29370781
[TBL] [Abstract][Full Text] [Related]
13. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Napolitano S; Ciardiello D; De Falco V; Martini G; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Fazio N; Di Maio M; Del Tufo S; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
Int J Cancer; 2023 Oct; 153(8):1520-1528. PubMed ID: 37391938
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Aparicio J; Virgili Manrique AC; Capdevila J; Muñoz Boza F; Galván P; Richart P; Oliveres H; Páez D; Hernando J; Serrano S; Vera R; Hernandez-Yagüe X; Gallego RÁ; Riesco-Martinez MC; García de Albeniz X; Maurel J
Clin Transl Oncol; 2022 Nov; 24(11):2155-2165. PubMed ID: 35761123
[TBL] [Abstract][Full Text] [Related]
18. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
19. Tumour location and efficacy of first-line EGFR inhibitors in
Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Watanabe J; Maeda H; Nagasaka T; Yokota M; Hirata K; Akazawa N; Kagawa Y; Yamada T; Shiozawa M; Ando T; Kato T; Mishima H; Sakamoto J; Oba K; Nagata N
Int J Cancer; 2022 Dec; 151(12):2172-2181. PubMed ID: 35723084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
